NCT Number: NCT05730712
Phase:
Trial Summary: This phase II trial tests how well pertuzumab, trastuzumab, hyaluronidase-zzxf and enzalutamide works in treating patients with castration-resistant prostate cancer that has spread from where it first – see clinicaltrials.gov for information and location
Clinicaltrials.gov
Trial Sponsor(s): Mayo Clinic
Acronym:
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives